Document is current
Any future updates will be listed below
-
Authors
Li, Weimei
Xia, Yuhua
Li, Yongzhao
Wu, Xing
Shi, Lin
-
Funding
Funding for this research was provided by:
Shanghai Key Clinical Research Center Fund (Grant No.2023ZZ02006)
- License Information
-
More Information
Article History
Received: 1 February 2026
Accepted: 1 April 2026
First Online: 15 April 2026
Declarations
:
: This study was approved by the Institutional Review Board (IRB) of the Sixth People’s Hospital of Shanghai, China (Approval No.:2025-KY-105(K) Date of Review:2025-03-27). The study was conducted in accordance with the Good Clinical Practice (GCP) guidelines and the Ethical Review Guidelines for Drug Clinical Trials issued by the National Medical Products Administration (NMPA) of the People’s Republic of China, as well as the principles of ICH-GCP. It also adheres to the requirements of the Declaration of Helsinki and complies with relevant laws and regulations in China.Written informed consent was obtained from all individual participants included in the study.
: Not applicable.
: The authors declare no competing interests.
